Question to the Foreign, Commonwealth & Development Office:

To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what proportion of the Official Development Assistance budget is allocated to initiatives tackling antimicrobial resistance.

The UK is a global leader in tackling antimicrobial resistance (AMR) and supports action though its multilateral, bilateral and research investments. It is not possible to identify the AMR element of all such spending.

Direct AMR spend includes, but is not limited to: i) the UK's Fleming Fund programme which strengthens drug-resistance surveillance systems across low- and middle-income countries in Africa, Asia and the Caribbean (£57.5 million in 2023-24); ii) the UK Global Antimicrobial Innovation Fund (GAMRIF) which supports Research & Development into products and solutions that reduce the threat of AMR in low and middle income countries (£16.4 million in 2023-24); iii) FCDO's funding to product development partnerships in 2024/25 included over £32 million to the Medicines for Malaria Venture, TB Alliance and the Mahidol-Oxford Tropical Medicine Research Unit's DeTACT project to develop new antimalarials and treatments for drug-resistant malaria and tuberculosis and to protect the effectiveness of existing medicines.

Official Development Assistance (ODA) allocations and the impact on programmes are being worked through following the decision to reduce UK ODA from 0.5 per cent of gross national income to 0.3 per cent in 2027. We will set out our spending plans following the completion of the spending review.